DNA can sustain serious injuries called double strand breaks, in which both strands of the helix snap. These breaks are among the most dangerous forms of DNA damage and immediately trigger the cell's ...

Growing customer use of artificial intelligence (AI) alongside the continued draw of live sports and major gaming releases has resulted in record levels of data consumption across the networks of ...

The FIX Trading Community has made recommendations for using the FIX Protocol for the upcoming European consolidated tapes covering equities and bonds. Jim Kaye, executive director of FIX, tells ...

Getting something for nothing is rare these days, but O2 is bucking the trend this December. The popular UK mobile network - which is now part of Virgin Media - is spreading some serious festive cheer ...

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome, supporting a bullish outlook. KYTX's Miv-cel achieved significant clinical improvements and ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Virgin Media O2 has released its 2025 Year in Review, revealing record levels of data consumption in the UK, including an 8 per cent rise in broadband usage and an 18 per cent rise in mobile traffic.

WASHINGTON — A defense policy bill expected to be voted on this week does not include provisions that would have ensured the military’s ability to purchase the technical data, parts and information ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel), during two ...

– 96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity Observed at a Median 15.9-months of Follow-up, with Responses Continuing to ...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.